Unpartnered Products: Potential Biopharma Game Changers
This article was originally published in Start Up
Executive Summary
As the pharmaceutical landscape continues to consolidate through acquisitions and partnerships, the untapped market of unpartnered products represents a potential multibillion-dollar opportunity. This analysis, derived from Informa’s Medtrack pharmaceutical intelligence and deals database, delves into the private company pipeline landscape, examining unpartnered candidates by therapy area and phase of development.